Human Papillomavirus Vaccination

"This clinical review outlines the efficacy, safety, and recommendations for HPV vaccination, which prevents cancers caused by human papillomavirus (HPV). The article highlights the long term protection offered by vaccines (e.g., 9-valent Gardasil 9), the dramatic reduction in HPV related infections and precancers post vaccination, and current U.S. guidelines for routine immunization (ages 9–26) and shared decision making (ages 27–45). Despite high vaccine safety, coverage remains suboptimal, underscoring the need for provider led education and catch up campaigns

"This clinical review outlines the efficacy, safety, and recommendations for HPV vaccination, which prevents cancers caused by human papillomavirus (HPV). The article highlights the long term protection offered by vaccines (e.g., 9-valent Gardasil 9), the dramatic reduction in HPV related infections and precancers post vaccination, and current U.S. guidelines for routine immunization (ages 9–26) and shared decision making (ages 27–45). Despite high vaccine safety, coverage remains suboptimal, underscoring the need for provider led education and catch up campaigns